The use of eculizumab in gemcitabine induced thrombotic microangiopathy

BACKGROUND: Thrombotic microangiopathy (TMA) secondary to gemcitabine therapy (GiTMA) is a very rare pathology that carries a poor prognosis, with nearly half of the cases progressing to end stage renal disease. GiTMA is most commonly associated with adenocarcinomas, most notably pancreatic cancers....

Full description

Saved in:
Bibliographic Details
Published in:BMC Nephrol
Main Authors: Krishnappa, Vinod, Gupta, Mohit, Shah, Haikoo, Das, Abhijit, Tanphaichitr, Natthavat, Novak, Robert, Raina, Rupesh
Format: Artigo
Language:Inglês
Published: BioMed Central 2018
Subjects:
Case Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5767063/
https://ncbi.nlm.nih.gov/pubmed/29329518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-018-0812-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items